42 results about "Ischemic brain" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

The invention discloses application of (20S)-ginsenoside Rh1 in preparation of drugs for preventing and / or improving cerebral arterial thrombosis, and relates to the technical field of medical application of natural drugs. The invention verifies that (20S)-ginsenoside Rh1 up-regulates the expression of an anti-apoptosis gene by promoting STAT3 phosphorylation and translocation to a cell nucleus, so that the (20S)-ginsenoside Rh1 plays a role in protecting neuronal injury induced by sugar oxygen deprivation. In MCAO model mice, the (20S)-ginsenoside Rh1 obviously relieves the symptom of ischemic cerebral apoplexy and has positive influence on neurodegenerative events related to cerebral infarction, and the anti-apoptosis and neuroprotection effects are most prominent. Mechanism research shows that (20S)-ginsenoside Rh1 plays a therapeutic role in PC12 cell and MCAO model mice by activating a JAK2 / STAT3 signal channel.

The invention belongs to the field of biological medicines, and provides a construction method of a photochemically induced mouse cerebral ischemia model, which comprises the following steps: S1, inducing anesthesia of a mouse, and ensuring that the mouse is continuously in an anesthesia state; s2, in the lateral position of the mouse, unhairing and disinfecting the face on one side, and cutting from the face of the mouse to expose the proximal end position of the M3 segment of the middle cerebral artery of the mouse or the cross point of reverse extension lines of branch blood vessels of the middle cerebral artery; s3, injecting a photosensitizer into the mouse, and after the photosensitizer circulates uniformly in the body of the mouse, irradiating the proximal end of the M3 segment of the middle cerebral artery or the cross point of the reverse extension line of the branch blood vessel of the middle cerebral artery after laser focusing; s4, after laser irradiation is finished, the skin is sutured, anesthesia is stopped, and the wound of the mouse is coated with an analgesic. The model obtained by the construction method of the photochemically induced mouse cerebral ischemia model provided by the invention has a larger infarct volume, and the infarct invades the subcortical brain region, so that the pathological characteristics of ischemic brain tissues are more obvious.

The present invention discloses the use of cytisine-N-methylene-(5,7,4'-trihydroxy) isoflavone in the preparation of a drug for treating cerebral infarction. The invention relates to the fields of medicine, natural products, traditional Chinese medicine, and functional foods. The compound has both alkaloid and isoflavone structures, a novel structure, and good drugability. It also contains both flavonoid and alkaloid structural characteristics and is combined with any excipient or carrier acceptable in pharmaceutical, nutritional, and food science. The compound of the present invention can be used as an active ingredient in the treatment of cerebral infarction, inhibiting ischemic brain damage. It not only has a significant therapeutic effect on cerebral infarction, but also possesses multi-level, multi-target comprehensive pharmacological effects and targeted treatment of various pathological mechanisms.

Disclosed is a non-invasive system and related methods to deliver electrical current to ischemic brain tissue rapidly with minimal set up, to treat acute ischemic stroke via direct cytoprotection and by collateral blood flow enhancement promoting recanalization of occluded vessel. In one embodiment, the system includes a cap with plurality of electrodes which are operable in combination to deliver an electrical current when in contact onto skin of the head region of the subject. In one embodiment, the electrical current delivery is individualized to target each individual's ischemic tissue only. In one embodiment, the electrode positioning can be selected from pre-determined electrode montages according to the location of the ischemia and vessel occlusion site. In one embodiment, the system can be applied as a standalone treatment or adjunct to reperfusion therapies to salvage the at-risk ischemic tissue (aka penumbra) and improve patient outcomes.

The present application discloses a method, apparatus, device and medium for constructing a spatial knowledge graph database of stroke, relating to the technical field of big data analysis. The present application utilizes the Tongyi Qianwen 2.1 model to deeply mine and analyze publicly available papers, identify and label the spatial distribution of genes, physiological regions, and pathological regions related to ischemic stroke, and display them in the form of a spatial knowledge graph database of stroke. The present application utilizes the natural language processing ability of the Tongyi Qianwen 2.1 model to automatically extract genes and their spatial distribution information from the literature and constructs a dynamically updated knowledge graph, solving the problems of low data integration efficiency, insufficient annotation accuracy, and insufficient dynamic association in the study of stroke spatial heterogeneity in the prior art.

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

The invention discloses low-temperature injectable hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Hydrogel is prepared from high-molecular-weight hyaluronic acid grafted with vitamin E and poly (N-isopropylacrylamide), the hydrogel is in an injectable liquid state at 4 DEG C, and a drug capsaicin (CPZ) wrapped by micelle is loaded and injected into the brain from the brain in a stereotactic mode. The pharmaceutical composition can temporarily maintain local low temperature of brain tissue and release capsaicin, reduce local metabolic activity of ischemic brain tissue, temporarily inhibit biogenesis, reduce NADH, FADH2 and other reducing equivalents and ADP accumulation, reduce the possibility of electron leakage in an electron transport chain, and improve the bioavailability of ischemic brain tissue. Vitamin E is added to reduce superoxide anions (O2 <.->) generated by reduction reaction of oxygen and leaked electrons in the reperfusion process, and vitamin E can promote ROS removal, synergistically alleviate oxidative stress and subsequent inflammation, and comprehensively improve cerebral ischemia reperfusion injury.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The present invention relates to a composition containing gintonin as an active ingredient for the prevention and treatment of ischemic cerebrovascular disorders, including cerebral infarction. The gintonin of the present invention can reduce the volume of cerebral infarction and increase survival rates after cerebral infarction, making it useful for the prevention and treatment of cerebral infarction. Furthermore, pretreatment of human brain microvascular endothelial cells (HBMECs) with gintonin has been shown to have neuroprotective and injury-preventing effects, while posttreatment with gintonin has been shown to have neuroprotective and therapeutic effects. Mechanism verification revealed that gintonin is effective in restoring reduced nitric oxide (NO) levels, which are known to be involved in the onset and pathophysiology of cerebral infarction. Therefore, the use of the present invention may improve the prevention and treatment of ischemic cerebrovascular disorders, including cerebral infarction, and reduce medical costs.

A method for treating brain injury in a subject comprises administering a therapeutically effective amount of a PKM2 (pyruvate kinase M2) protein variant. The protein variant is delivered systemically and can reduce tissue damage after ischemic brain tissue reperfusion. The methods specifically involve the use of G415R mutants of PKM2 protein variants. The treatment is suitable for brain injury caused by hemorrhagic stroke and ischemic stroke. The PKM2 protein variants are ideally administered intravenously within one hour of reperfusion to maximize their therapeutic efficacy.

The invention relates to systems and methods for predicting ischemic brain tissue fate from multi-phase CT-angiography. More specifically, systems and methods are provided that enable meaningful prediction of core, penumbra and perfusion from mCTA images using software that has been trained via machine learning to interpret mCTA images.

The invention relates to the technical field of active polypeptides, and discloses a polypeptide with ASIC1a selective inhibitory activity and application thereof. The amino acid sequence of the polypeptide is EDCIPKWKGCVNRHGDCCEGLECYVRR KSFEVCIPKTPKT, and the amino acid sequence of the polypeptide is shown in the specification. According to the polypeptide with ASIC1a selective inhibitory activity and the application thereof, the polypeptide can specifically inhibit channel current of ASIC1a and can effectively inhibit channel current of ASIC1b, the molecular weight is 4629.40 Da, and compared with a monoclonal antibody with large molecular weight, the polypeptide has good blood-brain barrier penetration rate, does not have remarkable cytotoxicity after being tested by experiments, and can be used for preparing a monoclonal antibody with ASIC1a selective inhibitory activity. The possibility of causing human immune response is low, potential unsafe factors are relatively few, and the compound can be used for preparing neuroprotective drugs for treating ischemic brain injury caused by cerebral arterial thrombosis.

The invention relates to a polypeptide of SEQ ID NO: 1 for use in the treatment of acute ischaemic stroke (AIS) or in the prevention of the complications of AIS in an adult mammalian subject. The polypeptide can be used in patients in whom AIS is followed by reperfusion of ischemic brain tissue, or in patients in whom AIS is not followed by reperfusion of ischemic brain tissue (patients with permanent cerebral ischemia).

The invention discloses a targeted delivery preparation as well as a preparation method and application thereof, and belongs to the technical field of biology and new medicine. The targeted delivery preparation comprises an agent A and an agent B in a ratio of (0.1-0.3) g: (2-5) mL; the agent A comprises nasal brain targeting peptide modified stem cell factor liposome freeze-dried powder and gel dry powder, the amino acid sequence of the nasal brain targeting peptide is as shown in SEQ ID NO.1, and the gel dry powder is formed by self-crosslinking mangiferin and rutin; and the agent B is a normal saline solution containing carboxymethyl chitosan. The targeted delivery preparation not only can meet long-time stable storage, but also can enhance the nasal-brain delivery efficiency of stem cell drugs. Besides, the targeted delivery preparation can be used independently or in combination with other treatment drugs, and is used for treating ischemic cerebral diseases, especially cerebral arterial thrombosis.

Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amyotrophic lateral sclerosis, cerebral palsy, stroke / ischemic brain damage, and migraine headaches.

The invention belongs to the technical field of biological medicine, and particularly relates to application of phthalide isoquinoline alkaloid in corydalis amabilis to preparation of a medicine for resisting cerebral ischemia. According to the application disclosed by the invention, corydalis amabilis with definite anti-cerebral ischemia activity is taken as a research object, and the anti-cerebral ischemia activity target P21 protein activating enzyme 2 of the corydalis amabilis is obtained and identified from ischemic brain tissues of middle cerebral artery occlusion (MCAO) rats by using a molecular target'hooking 'technology based on thermal proteomics. Then, the inventor detects the binding force of a monomeric compound and a target protein in corydalis amabilis by using a surface plasmon resonance technology, and finally screens out a key substance phthalide isoquinoline alkaloid, which exerts the anti-cerebral ischemia activity, in corydalis amabilis.

The present application relates to the use of compound 1-[4-ethoxy-3-[5-(6,7-dihydro-1-methyl-7-oxy-3-n-propyl-1H-pyrazolo[4,3-d]pyrimidine)] benzenesulfonyl]-3,5-dimethylpiperazine, particularly in the preparation of drugs for the prevention and treatment of diseases caused by cerebral ischemia, particularly ischemic cerebral neuron damages and necrosis.

The invention belongs to the technical field of pharmacy, and particularly relates to application of 3-butyl-6-hydrazinoisobenzofuran-1-one in preparation of a medicine for treating cerebral arterial thrombosis. The structural formula of the 3-butyl-6-hydrazino isobenzofuran-1-ketone is as shown in the specification. The 3-butyl-6-hydrazino isobenzofuran-1-ketone prepared by the preparation method disclosed by the invention has excellent anti-platelet aggregation effect, neuroprotective activity and antithrombotic activity. Derivatives, isomers or optical isomers, racemate, pharmaceutical salts, hydrates, solvates and pharmaceutical carriers or excipients of the compound can be applied to preparation of drugs for preventing or treating cardiovascular and cerebrovascular diseases and complications thereof caused by thrombus. .

The present invention relates to a pharmaceutical composition for preventing or treating stroke, comprising a pressed extract, a solvent extract or a fraction of a solvent extract of Juglans mandshurica fruit. The Juglans mandshurica fruit exhibits a protective effect on brain tissue (brain cells) against ischemic brain tissue damage induced by middle cerebral artery occlusion and reduces infarction, and thus can be usefully used for a pharmaceutical composition or health functional food for preventing, ameliorating or treating stroke.

The invention discloses a construction method and device of a cerebral apoplexy space knowledge graph database, equipment and a medium, and relates to the technical field of big data analysis. According to the application, the Tonyuqian question 2.1 model is utilized to deeply mine, analyze and publically obtain papers, identify and mark spatial distribution conditions of ischemic cerebral apoplexy genes, physiological regions and pathological regions, and the spatial distribution conditions are displayed in the form of a cerebral apoplexy spatial knowledge graph database. According to the method, genes and spatial distribution information thereof are automatically extracted from literatures, and a dynamically updated knowledge graph is constructed, so that the problems of low data integration efficiency, insufficient labeling accuracy, insufficient dynamic association and the like in cerebral apoplexy spatial heterogeneity research in the prior art are solved.

The invention discloses application of MIF as a target spot in preparation of a medicine for monitoring or treating ischemic white matter injury. The invention creatively finds application of MIF as a target spot in preparation of a medicine for monitoring or treating ischemic white matter injury. MIF is highly expressed in microglial cells in a demyelination area of ischemic white matter injury, and can be applied to disease monitoring of ischemic white matter injury. By inhibiting the expression of MIF, the severity of demyelination in ischemic white matter injury and chemotaxis of meninx B cells can be relieved, so that the compound can be applied to preparation of medicines for treating ischemic white matter injury, and has good clinical application value.

The invention discloses application of a reagent for detecting abundance of intestinal flora markers in preparation of a cerebral apoplexy in-vitro diagnosis product. The method comprises the following steps: performing 16S v4 region amplicon sequencing on bacterial components in faeces of healthy people and cerebral arterial thrombosis people to obtain the abundance of bacteria, finding out flora of 18 specific genus and species as microbial markers through screening operation, and constructing a cerebral arterial thrombosis risk prediction model. Verification queue data proves that the cerebral arterial thrombosis risk prediction model is high in prediction sensitivity and good in specificity, cerebral arterial thrombosis patients and healthy individuals can be effectively distinguished in multiple samples, and the accuracy is 93% or above, so that the flora can be used as a cerebral arterial thrombosis detection marker, and the cerebral arterial thrombosis risk prediction model can be used for detecting cerebral arterial thrombosis. A reagent for detecting the abundance of the intestinal flora marker can be used for preparing a cerebral arterial thrombosis in-vitro diagnosis kit, so that a foundation is laid for early diagnosis, prevention and treatment as well as research of cerebral arterial thrombosis.

The present invention relates to: a composition for preventing or treating a stroke and a food composition for preventing or alleviating a stroke, the compositions containing sobrerol; and the like. The present invention contains, as an active ingredient, sobrerol or a pharmaceutically acceptable salt thereof to have a brain protection effect against ischemic brain tissue damage caused by middle cerebral artery occlusion / reperfusion, and reduces the size of an infarction in the internal capsule, and thus can be effectively usable in the pharmaceutical and food fields for preventing, alleviating, or treating a stroke.

The invention discloses an AMD3100 nucleus-immobilizing lipid nanoparticle and an application of the AMD3100 nucleus-immobilizing lipid nanoparticle. The invention provides a nucleus-immobilizing lipid nanoparticle. The nucleus-immobilizing lipid nanoparticle is prepared from a DOPA (Dioctyl-Polyamide) modified calcium phosphate core, DSPE-PEG2000-AMD3100, DSPE-PEG2000, cholesterol and DOTAP (Dioctyl-Polyamide), the structure of the DSPE-PEG2000-AMD3100 is as shown in a formula I which is described in the specification; in the DOPA modified calcium phosphate core, the DOPA is loaded on the surface of the calcium phosphate core. According to the invention, AMD3100 is used as a target head of the drug delivery carrier to be modified on the solid nucleus lipid nanoparticle carrier, so that a large amount of therapeutic drugs can be delivered to damaged cells and newborn cells in an ischemic area, targeted drug delivery in the ischemic brain area is realized, and the drug treatment effect is improved. # imgabs0 #

The present application relates to a gene for regulating cholesterol metabolism and a micropeptide MP19 encoded thereby, and a use thereof, and also relates to a use of the micropeptide in the preparation of a drug or pharmaceutical composition for detecting, preventing, alleviating or treating diseases associated with abnormal cholesterol metabolism, said diseases comprising atherosclerosis, age-related macular degeneration, hyperlipidemia, non-alcoholic hepatitis, hepatocellular carcinoma, coronary heart disease, ischemic stroke, and obesity. By means of endogenous overexpression or exogenous synthesis of the micropeptide, diseases associated with abnormal cholesterol metabolism can be effectively prevented, alleviated, or treated.

This invention provides a drug delivery system and its application based on brain microvascular endothelial cells, comprising stimulated brain microvascular endothelial cells, wherein the stimulation is performed by culturing in a culture system containing supernatant of brain microvascular endothelial cells cultured under glucose and oxygen deprivation. This invention solves the problems of targeting and timeliness in treating blood-brain barrier damage after ischemic stroke under current technologies. It can regulate the BBB while supporting its function and structure, maintaining and repairing BBB function after reperfusion, thus improving the prognosis of stroke treatment. The cell preparations in this invention are widely available and easily obtained, and can rapidly repair the blood-brain barrier. Furthermore, the cell preparations in this invention can target ischemic brain sites and can be administered via simple intravenous injection, facilitating clinical operation.

The present invention belongs to the field of biomedicine technology, and in particular to the use of targeted liposomes as active ingredients in the preparation of medicines for treating ischemic brain injury. The targeted liposomes for treating ischemic stroke of the present invention are prepared by fusion of liposomes and platelet-neutrophil aggregate membranes, achieving efficient and specific targeting of ischemic brain areas, while effectively reducing brain tissue infarction and damage to new areas, and alleviating brain inflammation through multi-pathway regulation. It can be used as an active ingredient for the preparation of medicines for treating ischemic brain injury. When the targeted liposomes are further loaded with rutin drugs, a synergistic therapeutic effect is achieved. The liposome medicine of the present invention can be used as an active ingredient and has good application prospects in the treatment of ischemic brain injury diseases.